{
    "clinical_study": {
        "@rank": "114394", 
        "arm_group": {
            "arm_group_label": "Roflumilast", 
            "description": "Participants prescribed roflumilast (Daxas\u00ae) according to local guidelines and marketing authorization."
        }, 
        "brief_summary": {
            "textblock": "A patient registry  to capture real life data and demonstrate the performance of roflumilast\n      (Daxas\u00ae) in a standard clinical practice."
        }, 
        "brief_title": "Patient Registry of Roflumilast In Real Life", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Obstructive Pulmonary Disease", 
        "condition_browse": {
            "mesh_term": [
                "Lung Diseases", 
                "Respiration Disorders", 
                "Pulmonary Disease, Chronic Obstructive", 
                "Lung Diseases, Obstructive"
            ]
        }, 
        "detailed_description": {
            "textblock": "The drug being tested in this observational study design is called roflumilast, but not as\n      an therapeutic intervention. Roflumilast is approved for and marketed globally for\n      maintenance treatment of severe Chronic Obstructive Pulmonary Disease (COPD) associated with\n      chronic bronchitis in adult patients with a history of frequent exacerbations as add on to\n      bronchodilator treatment.\n\n      This study will capture real life data and demonstrate the performance of roflumilast in a\n      standard clinical practice. The study will enroll approximately 1350 (EU)+600(North Asia)\n      patients. This multi-centre trial will be conducted in at least 4 EU and 2 North Asian\n      countries.\n\n      The overall time to participate in this study is 12 months. No visits, diagnostic procedures\n      or monitoring will take place, which would not happen had the patient not been included in\n      the study.\n\n      Participants will be followed according to usual practice and data recorded approximately at\n      6 months and at 12 months of roflumilast treatment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Signed informed consent to the data collection\n\n          -  Roflumilast (Daxas\u00ae) treatment initiated in Roflumilast (Daxas\u00ae) na\u00efve patients at\n             the time of registry\n\n        Exclusion Criteria:\n\n        There are no exclusion criteria per se. However it is expected that patients are treated\n        according to locally approved marketing authorisation."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Participants prescribed roflumilast (Daxas\u00ae) according to local guidelines and marketing\n        authorization.\n\n        The registry sites will comprise hospitals, and office-based physicians. The investigators\n        will be mainly pulmonologists, or as per the standard practice of the specific country."
            }
        }, 
        "enrollment": {
            "#text": "1950", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02015767", 
            "org_study_id": "RO-2455-407-RD", 
            "secondary_id": "U1111-1146-5619"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Drug therapy", 
        "lastchanged_date": "May 26, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Haskova", 
                        "country": "Bulgaria"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Novi Iskar", 
                        "country": "Bulgaria"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pazardjik", 
                        "country": "Bulgaria"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pleven", 
                        "country": "Bulgaria"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Razgrad", 
                        "country": "Bulgaria"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ruse", 
                        "country": "Bulgaria"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sofia", 
                        "country": "Bulgaria"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Troyan", 
                        "country": "Bulgaria"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Varna", 
                        "country": "Bulgaria"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Vratsa", 
                        "country": "Bulgaria"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Arendal", 
                        "country": "Norway"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bergen", 
                        "country": "Norway"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Elverum", 
                        "country": "Norway"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fredrikstad", 
                        "country": "Norway"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kongsvinger", 
                        "country": "Norway"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sandvika", 
                        "country": "Norway"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Skien", 
                        "country": "Norway"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Straume", 
                        "country": "Norway"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "T\u00f8nsberg", 
                        "country": "Norway"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Bulgaria", 
                "Norway"
            ]
        }, 
        "number_of_groups": "1", 
        "official_title": "Patient Registry of Roflumilast In Real Life", 
        "overall_contact": {
            "email": "medicalinformation@tpna.com", 
            "last_name": "Takeda Study Registration Call Center", 
            "phone": "800-778-2860"
        }, 
        "overall_official": {
            "affiliation": "Takeda", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Greece: Ministry of Health and Welfare", 
                "Greece: Ethics Committee", 
                "Bulgaria: Bulgarian Drug Agency", 
                "Bulgaria: Ethical Committee to the Ministry of Health", 
                "Norway: Regional Committees for Medical and Health Research Ethics", 
                "Norway: Norwegian Medicines Agency", 
                "Slovakia: Ethics Committee", 
                "Slovakia: Insurance Company (Final approval and oversight)"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Number of exacerbations observed during the study period and per patient per year", 
            "measure": "Number of observed exacerbations", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02015767"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Severity of exacerbations (proportion of exacerbations requiring systemic corticosteroid treatment and/or antibiotics or requiring hospitalization).", 
                "measure": "Severity of exacerbations", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Seasonal variation of exacerbation during Roflumilast treatment.", 
                "measure": "Seasonal variation of exacerbation", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Number of hospitalizations due to Chronic obstructive pulmonary disease (COPD) exacerbations per patient per year.", 
                "measure": "Number of hospitalizations due to COPD exacerbations", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Change in lung function parameters parameters FEV1(Forced Expired Volume measured after 1 second expiration)  and FEV1/FVC (Forced Vital Capacity) from Baseline to the last recorded value and to the end of the study.", 
                "measure": "Change from Baseline in lung function parameters (FEV1 and FEV1/FVC)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Month 12"
            }, 
            {
                "description": "Change in blood oxygen saturation assessed with pulse oximetry from Baseline to the last recorded value and the end of the study.", 
                "measure": "Change from Baseline in blood oxygen saturation", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Month 12"
            }, 
            {
                "description": "Estimated percentage of prescribed doses taken since the last date of data collection.", 
                "measure": "Percentage of compliance to treatment", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Changes in concomitant administration of COPD maintenance treatments since start of roflumilast treatment.", 
                "measure": "Changes in concomitant administration of COPD maintenance treatments", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "measure": "Health status using the COPD Assessment Questionnaire (CAT)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Month 6 and Month 12"
            }, 
            {
                "description": "Change in breathlessness assessed using the Modified Medical Research Council (mMRC) dyspnoea scale, from Baseline to the end of observation.", 
                "measure": "Change from Baseline in breathlessness", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Month 12"
            }, 
            {
                "description": "An ADR is a response to an observed medicinal product which is noxious and unintended resulting not only from the authorised use of a medicinal product at normal doses, but also from medication errors and uses outside the terms of the marketing authorisation, including the misuse and abuse of the medicinal product.", 
                "measure": "Number of Participants with adverse Drug Reactions (ADRs)", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }
        ], 
        "source": "Takeda", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Takeda", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}